Latest news with #CharlesRiverLabs
Business Insider
5 days ago
- Business
- Business Insider
Evercore ISI Reaffirms Their Buy Rating on Charles River Labs (CRL)
Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Charles River Labs (CRL – Research Report) yesterday and set a price target of $170.00. The company's shares closed yesterday at $143.22. Confident Investing Starts Here: Anderson CFA covers the Healthcare sector, focusing on stocks such as CVS Health, Align Tech, and Quest Diagnostics. According to TipRanks, Anderson CFA has an average return of -6.7% and a 42.08% success rate on recommended stocks. In addition to Evercore ISI, Charles River Labs also received a Buy from Redburn Atlantic's Jamie Clark in a report issued on May 23. However, on June 3, William Blair maintained a Hold rating on Charles River Labs (NYSE: CRL). Based on Charles River Labs' latest earnings release for the quarter ending March 29, the company reported a quarterly revenue of $984.17 million and a net profit of $25.47 million. In comparison, last year the company earned a revenue of $1.01 billion and had a net profit of $67.33 million Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRL in relation to earlier this year. Last month, Joseph W LaPlume, the EVP, Corp Strategy & Develop of CRL sold 500.00 shares for a total of $72,705.00.
Business Insider
08-05-2025
- Business
- Business Insider
Positive Report for Charles River Labs (CRL) from Evercore ISI
Charles River Labs (CRL – Research Report) received a Buy rating and price target from Evercore ISI analyst Elizabeth Anderson CFA yesterday. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Anderson CFA is an analyst with an average return of -6.6% and a 42.49% success rate. Anderson CFA covers the Healthcare sector, focusing on stocks such as Icon, Charles River Labs, and CVS Health. Currently, the analyst consensus on Charles River Labs is a Hold with an average price target of $152.50. Based on Charles River Labs' latest earnings release for the quarter ending December 28, the company reported a quarterly revenue of $1 billion and a GAAP net loss of $213.41 million. In comparison, last year the company earned a revenue of $1.01 billion and had a net profit of $187.08 million Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRL in relation to earlier this year. Most recently, in February 2025, Birgit Girshick, the Corporate Executive VP & COO of CRL bought 1,514.00 shares for a total of $249,249.82.
